We Are One Seven LLC Grows Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

We Are One Seven LLC raised its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 18.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,557 shares of the specialty pharmaceutical company’s stock after buying an additional 856 shares during the period. We Are One Seven LLC’s holdings in Jazz Pharmaceuticals were worth $712,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ellis Investment Partners LLC increased its stake in shares of Jazz Pharmaceuticals by 67.8% during the third quarter. Ellis Investment Partners LLC now owns 9,189 shares of the specialty pharmaceutical company’s stock worth $1,163,000 after purchasing an additional 3,713 shares in the last quarter. Centric Wealth Management increased its stake in shares of Jazz Pharmaceuticals by 12.1% during the third quarter. Centric Wealth Management now owns 6,952 shares of the specialty pharmaceutical company’s stock worth $865,000 after purchasing an additional 751 shares in the last quarter. Fulton Bank N.A. increased its stake in shares of Jazz Pharmaceuticals by 10.6% during the third quarter. Fulton Bank N.A. now owns 2,299 shares of the specialty pharmaceutical company’s stock worth $295,000 after purchasing an additional 220 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in shares of Jazz Pharmaceuticals by 231.0% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 54,413 shares of the specialty pharmaceutical company’s stock worth $7,757,000 after purchasing an additional 37,975 shares in the last quarter. Finally, Boston Partners increased its stake in shares of Jazz Pharmaceuticals by 2.7% during the second quarter. Boston Partners now owns 1,341,023 shares of the specialty pharmaceutical company’s stock worth $191,116,000 after purchasing an additional 35,360 shares in the last quarter. 87.62% of the stock is owned by institutional investors.

In related news, Director Catherine A. Sohn sold 726 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $135.65, for a total transaction of $98,481.90. Following the sale, the director now directly owns 9,574 shares of the company’s stock, valued at approximately $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,597 shares of company stock worth $764,057. Company insiders own 4.30% of the company’s stock.

JAZZ has been the subject of a number of research reports. Mizuho set a $148.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, July 3rd. BidaskClub lowered shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday. HC Wainwright restated a “hold” rating and set a $147.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 8th. Evercore ISI restated a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, August 12th. Finally, TheStreet upgraded shares of Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $168.43.

Shares of JAZZ stock traded up $3.21 during trading hours on Friday, hitting $121.17. The company had a trading volume of 37,580 shares, compared to its average volume of 477,824. The company’s fifty day moving average is $127.86 and its 200 day moving average is $133.87. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. Jazz Pharmaceuticals PLC has a fifty-two week low of $113.52 and a fifty-two week high of $165.66. The stock has a market capitalization of $6.68 billion, a PE ratio of 9.90, a price-to-earnings-growth ratio of 1.46 and a beta of 1.11.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.16 by $0.49. Jazz Pharmaceuticals had a net margin of 32.99% and a return on equity of 27.72%. The firm had revenue of $534.13 million for the quarter, compared to analyst estimates of $507.23 million. During the same period in the prior year, the business posted $3.49 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 13.44 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: What is a Reverse Stock Split?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.